webinar

Strategic Considerations for Clinical Development Programs in Emerging Biopharma

Register now

May 25, 2016

Register Save to Calendar

 

Summary

At small biotech companies, the race is on: investor demand, regulatory complexity, crunched timelines, stakeholder pressures, and limited resources are just a few of the challenges. We recognize that yet another challenge is finding suitable partners capable of providing both flexibility and access to the capabilities your product and company desire, while aligning to your budget. By examining your product development through the lens of an investor, it becomes clear that early planning and design are crucial to navigating your clinical studies and commercial pathways.

By registering for this webinar, learn from Quintiles leader Rick Sax about the strategic considerations you should consider in order to navigate the clinical development of your product as an emerging biopharmaceutical firm: 

  • Design with the end in mind, from drug discovery, IND, through approval
  • Perspectives: investors vs stakeholders vs market
  • Balance investment opportunity & risk
  • Understand the healthcare system and your market
  • Thinking ahead without investing major resources
  • Key questions to ask yourself and your team throughout development

Speaker

Rick Sax, M.D.
Senior Vice President
Quintiles Advisory Services

Frederic “Rick” Sax, M.D. leads advisory solutions for product development – leveraging design expertise at every step of the drug development spectrum to help partners make knowledge-based decisions about the benefit-risk-value trade-offs of their compounds. 

Dr. Sax joined Quintiles from AstraZeneca’s clinical development leadership team where he served as Vice President, Clinical Design Strategies. For more than a decade, Dr. Sax has led the design of solutions to enhance the quality of program and trial design while driving efficiencies in cost, time and process. Dr. Sax’s career spans nearly 20 years in the biopharmaceutical industry. Prior to joining the industry, he served as an academic cardiologist. Dr. Sax graduated with a B.A. in Biology and Philosophy from Yale University, and an M.D. from Columbia University.